These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38728438)

  • 21. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
    JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial Fibrillation.
    Poulet C; Wettwer E; Grunnet M; Jespersen T; Fabritz L; Matschke K; Knaut M; Ravens U
    PLoS One; 2015; 10(6):e0131432. PubMed ID: 26121051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium.
    Cappetta D; De Angelis A; Ciuffreda LP; Coppini R; Cozzolino A; Miccichè A; Dell'Aversana C; D'Amario D; Cianflone E; Scavone C; Santini L; Palandri C; Naviglio S; Crea F; Rota M; Altucci L; Rossi F; Capuano A; Urbanek K; Berrino L
    Pharmacol Res; 2020 Jul; 157():104781. PubMed ID: 32360273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain.
    Schauer A; Adams V; Kämmerer S; Langner E; Augstein A; Barthel P; Männel A; Fabig G; Alves PKN; Günscht M; El-Armouche A; Müller-Reichert T; Linke A; Winzer EB
    Circ Heart Fail; 2024 Jun; 17(6):e011107. PubMed ID: 38847102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced late INa induces proarrhythmogenic SR Ca leak in a CaMKII-dependent manner.
    Sag CM; Mallwitz A; Wagner S; Hartmann N; Schotola H; Fischer TH; Ungeheuer N; Herting J; Shah AM; Maier LS; Sossalla S; Unsöld B
    J Mol Cell Cardiol; 2014 Nov; 76():94-105. PubMed ID: 25173923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of late sodium current by Ca2+, calmodulin, and CaMKII in normal and failing dog cardiomyocytes: similarities and differences.
    Maltsev VA; Reznikov V; Undrovinas NA; Sabbah HN; Undrovinas A
    Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1597-608. PubMed ID: 18203851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
    Tanashat M; Manasrah A; Abouzid M
    Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
    Uthman L; Nederlof R; Eerbeek O; Baartscheer A; Schumacher C; Buchholtz N; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
    Cardiovasc Res; 2019 Aug; 115(10):1533-1545. PubMed ID: 30649212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The novel CaMKII inhibitor GS-680 reduces diastolic SR Ca leak and prevents CaMKII-dependent pro-arrhythmic activity.
    Lebek S; Plößl A; Baier M; Mustroph J; Tarnowski D; Lücht CM; Schopka S; Flörchinger B; Schmid C; Zausig Y; Pagratis N; Marchand B; Koltun DO; Hung WK; Ahmadyar S; Belardinelli L; Maier LS; Wagner S
    J Mol Cell Cardiol; 2018 May; 118():159-168. PubMed ID: 29614261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction.
    Zhang N; Feng B; Ma X; Sun K; Xu G; Zhou Y
    Cardiovasc Diabetol; 2019 Aug; 18(1):107. PubMed ID: 31429767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions.
    Zuurbier CJ; Baartscheer A; Schumacher CA; Fiolet JWT; Coronel R
    Cardiovasc Res; 2021 Dec; 117(14):2699-2701. PubMed ID: 33792689
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
    Riaz M; Guo J; Smith SM; Dietrich EA; Winchester DE; Park H
    Am J Cardiovasc Drugs; 2024 May; 24(3):455-464. PubMed ID: 38691312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calmodulin kinase II regulates atrial myocyte late sodium current, calcium handling, and atrial arrhythmia.
    Greer-Short A; Musa H; Alsina KM; Ni L; Word TA; Reynolds JO; Gratz D; Lane C; El-Refaey M; Unudurthi S; Skaf M; Li N; Fedorov VV; Wehrens XHT; Mohler PJ; Hund TJ
    Heart Rhythm; 2020 Mar; 17(3):503-511. PubMed ID: 31622781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atrial-selective targeting of arrhythmogenic phase-3 early afterdepolarizations in human myocytes.
    Morotti S; McCulloch AD; Bers DM; Edwards AG; Grandi E
    J Mol Cell Cardiol; 2016 Jul; 96():63-71. PubMed ID: 26241847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late INa increases diastolic SR-Ca2+-leak in atrial myocardium by activating PKA and CaMKII.
    Fischer TH; Herting J; Mason FE; Hartmann N; Watanabe S; Nikolaev VO; Sprenger JU; Fan P; Yao L; Popov AF; Danner BC; Schöndube F; Belardinelli L; Hasenfuss G; Maier LS; Sossalla S
    Cardiovasc Res; 2015 Jul; 107(1):184-96. PubMed ID: 25990311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
    Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
    Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reactive oxygen species-activated Ca/calmodulin kinase IIδ is required for late I(Na) augmentation leading to cellular Na and Ca overload.
    Wagner S; Ruff HM; Weber SL; Bellmann S; Sowa T; Schulte T; Anderson ME; Grandi E; Bers DM; Backs J; Belardinelli L; Maier LS
    Circ Res; 2011 Mar; 108(5):555-65. PubMed ID: 21252154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of late sodium current by Ca
    Fu C; Hao J; Zeng M; Song Y; Jiang W; Zhang P; Luo A; Cao Z; Belardinelli L; Ma J
    Exp Physiol; 2017 Jul; 102(7):818-834. PubMed ID: 28436159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes.
    Sag CM; Wagner S; Maier LS
    Free Radic Biol Med; 2013 Oct; 63():338-49. PubMed ID: 23732518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.